Navigation Links
Corgenix Secures $1,750,000 Asset Based Credit Facility Representing Initial Gross Proceeds of $1.109 Million
Date:10/6/2009

portfolio company, after their having performed extremely comprehensive due diligence on our company, bodes very well for the future of our Company."

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience advancing products through the FDA process. More information is available at www.corgenix.com.

About Summit Financial Resources L.P.

Summit Financial Resources is a nationally recognized provider of working capital financing to small and medium-sized businesses in a broad range of industries. With 16 offices nationwide and over 20 years of experience, Summit has established itself as one of the largest and fastest growing companies in its industry.

Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today
'/>"/>

SOURCE Corgenix Medical Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Corgenix Signs Technology Licensing Agreement With Japanese Government
2. Corgenix to Exhibit AspirinWorks(R) Test at ACC 2008 Meeting in Chicago
3. Corgenix Announces FDA Clearance for IgG Anti-AtherOx(R) Test Kit
4. Corgenix to Host Conference Call to Discuss Third Quarter Fiscal 2008 Results
5. Corgenix to Exhibit AspirinWorks(R) Test at ADA 2008 Meeting in San Francisco
6. Corgenix Expands Scientific Advisory Board
7. Corgenix to Host Conference Call to Discuss Fiscal 2008 Results
8. Corgenix Reports Fiscal 2008 Financial Results
9. Corgenix Receives Third U.S. Patent on AtherOx(R) Technology
10. Corgenix to Exhibit AspirinWorks(R) Test, Discuss New CHARISMA Trial Results at AHA 2008 Meeting
11. Corgenix to Host Conference Call to Discuss First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... April 21, 2015  scPharmaceuticals, Inc., a ... products for subcutaneous delivery, announced today that ... its investigational proprietary drug product, Furosemide Injection ... with congestive heart failure. Concurrently ... a proprietary patch pump.  The patch pump ...
(Date:4/21/2015)... CA (PRWEB) April 21, 2015 ... will sponsor and exhibit at the ACRP 2015 Global ... Lake City, Utah. The Association of Clinical Research Professionals ... clinical research conference solely focused on the conduct of ... training and development, and widely recognized industry certifications. , ...
(Date:4/21/2015)... 2015 Progyny, Inc., the new combined ... that it has secured additional capital from investors including ... One and Merck Serono Ventures. The funding will enable ... best fertility outcomes by aligning science, technology, clinics and ... for families seeking fertility solutions and we are committed ...
(Date:4/21/2015)... Springfield, Mo. (PRWEB) April 21, 2015 ... vessels, HOLLOWAY AMERICA is slated to discuss its custom ... also present its reimagined website, which launched just prior ... Wed. and Thurs. (April 21, 22 and 23) at ... than 12,000 representatives of the world’s largest and most ...
Breaking Biology Technology:scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 2scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 3PRC Clinical Sponsors The ACRP 2015 Global Conference And Meets Biotech Companies in the Salt Lake City Area. 2Announcing Progyny: Combining Best-in-Class Clinical Solutions with Consumer Expertise 2HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 2HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 3
...  AMPAC Fine Chemicals LLC (AFC), a wholly-owned ... has concluded an agreement with Chimerix, Inc. to validate ... in Chimerix,s broad spectrum antiviral drug candidate, CMX001, which ... smallpox.  Chimerix will provide the investigational drug product under ...
... FORT LEE, N.J., Aug. 11, 2011 Neurologix, ... of innovative gene therapies for disorders of the brain and ... three and six months ended June 30, 2011. ... a net loss of approximately $3.0 million, as compared with ...
... Genetics, Inc. (OTCQB: ILIU) announced today that CEO Lewis ... Management Access Conference at the Le Parker Meridien Hotel, 119 ... scheduled for Wednesday, Aug. 17 at 3:35 p.m. (EDT) in ... Interleukin,s management team will be available for one-on-one meetings ...
Cached Biology Technology:AMPAC Fine Chemicals Completes Contract Manufacturing Agreement for Smallpox Countermeasure API 2AMPAC Fine Chemicals Completes Contract Manufacturing Agreement for Smallpox Countermeasure API 3AMPAC Fine Chemicals Completes Contract Manufacturing Agreement for Smallpox Countermeasure API 4Neurologix Announces Second Quarter 2011 Financial Results 2Neurologix Announces Second Quarter 2011 Financial Results 3Neurologix Announces Second Quarter 2011 Financial Results 4Neurologix Announces Second Quarter 2011 Financial Results 5Neurologix Announces Second Quarter 2011 Financial Results 6Neurologix Announces Second Quarter 2011 Financial Results 7Neurologix Announces Second Quarter 2011 Financial Results 8Interleukin Genetics, Inc. to Present at the 2011 Wedbush Securities Life Sciences Management Access Conference 2
(Date:3/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced ... Strategic Business Report" report to their offering. This ... US$ Thousands by the following Segments: Face Biometrics, and Voice Biometrics. ... Canada , Japan , Europe ... & Africa , and ...
(Date:3/23/2015)... March 23, 2015  In the 2014 fiscal year, ... conviction losses. This figure accounts for a fraction of ... The Nilson Report, exceeds $11 billion globally. The polygraph ... a crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test ...
(Date:3/20/2015)... Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced the addition ... report to their offering. This report analyzes ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided for ...
Breaking Biology News(10 mins):Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... a group of plant viruses that cause devastating disease ... with The American Phytopathological Society (APS). , According ... University of Arizona's Department of Plant Sciences, the whitefly, ... (transmitter) for a large group of emerging plant viruses ...
... around the world die of this type of meningitis, according ... the disease is called, can even spark epidemics: in Africa ... the late 1990s. Without treatment, mortality among those who ... percent. Patients also run a high risk of serious ...
... But exactly what our tears are made of has remained a ... the complex design of tears. What we think of as tears, ... microscopic layers. The middle, watery layer ?what we normally think of ... mucus and an outer layer of fatty, oily substances collectively called ...
Cached Biology News:Tears reveal some of their deepest secrets to researchers 2Tears reveal some of their deepest secrets to researchers 3